Vitamin Shoppe (NYSE:VSI) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Vitamin Shoppe (NYSE:VSI) from a strong sell rating to a hold rating in a report published on Sunday, January 21st.

According to Zacks, “Vitamin Shoppe is a specialty retailer and direct marketer of nutritional products. It primarily sells vitamins, minerals, nutritional supplements, herbs, sports nutrition formulas, homeopathic remedies, green living products and health and beauty aids. Based in North Bergen, New Jersey, the company is recognized as an innovator in providing product information, associate training, and customer education. Information is available to consumers through unprecedented outlets including television, radio, friends, family, health practitioners, and the internet. It offers consumers the opportunity to take charge of their own health and wellness requirements, and supplement where necessary. At each store location, consumers can find a comprehensive Learning Center which offers free access to vital information about key health concerns and products. The Vitamin Shoppe is a strong supporter of health and wellness campaigns including Life Supplemented sponsored by the Council for Responsible Nutrition. “

Other analysts have also issued research reports about the company. Barclays cut their price objective on Vitamin Shoppe from $6.00 to $3.00 and set an equal weight rating for the company in a report on Thursday, November 9th. Morgan Stanley reissued an equal weight rating and set a $7.50 price target (down previously from $8.00) on shares of Vitamin Shoppe in a report on Monday, October 2nd. Finally, ValuEngine raised Vitamin Shoppe from a hold rating to a buy rating in a report on Thursday, October 5th. Three analysts have rated the stock with a sell rating and six have issued a hold rating to the company’s stock. The stock has an average rating of Hold and an average price target of $5.00.

Vitamin Shoppe (NYSE VSI) traded up $0.15 during mid-day trading on Friday, hitting $3.90. The stock had a trading volume of 362,292 shares, compared to its average volume of 811,550. The company has a quick ratio of 0.32, a current ratio of 2.07 and a debt-to-equity ratio of 0.59. Vitamin Shoppe has a 52-week low of $2.95 and a 52-week high of $23.25. The stock has a market capitalization of $89.92, a PE ratio of -0.37 and a beta of 0.59.

In other Vitamin Shoppe news, major shareholder Vintage Capital Management Llc bought 133,804 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were purchased at an average price of $4.28 per share, with a total value of $572,681.12. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Shah Capital Management acquired 300,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was purchased at an average cost of $3.83 per share, for a total transaction of $1,149,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 1,000,639 shares of company stock worth $4,387,647. Company insiders own 1.07% of the company’s stock.

A number of large investors have recently made changes to their positions in VSI. Macquarie Group Ltd. bought a new stake in Vitamin Shoppe during the 3rd quarter valued at $101,000. BNP Paribas Arbitrage SA boosted its position in Vitamin Shoppe by 2.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock valued at $108,000 after acquiring an additional 192 shares in the last quarter. Wolverine Trading LLC bought a new stake in Vitamin Shoppe during the 2nd quarter valued at $131,000. Crossmark Global Holdings Inc. boosted its position in Vitamin Shoppe by 122.8% during the 4th quarter. Crossmark Global Holdings Inc. now owns 31,320 shares of the specialty retailer’s stock valued at $138,000 after acquiring an additional 17,260 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in Vitamin Shoppe by 17,041.4% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,999 shares of the specialty retailer’s stock valued at $140,000 after acquiring an additional 11,929 shares in the last quarter. 99.86% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/12/zacks-investment-research-upgrades-vitamin-shoppe-vsi-to-hold-updated-updated-updated.html.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Get a free copy of the Zacks research report on Vitamin Shoppe (VSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply